Immutep Ltd has released a press release.
Immutep receives EMA scientific advice for Phase 3 in MBC
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immutep
- Immutep Quarterly Activities Report & Appendix 4C
- Immutep Receives A$3.4 million R&D French Tax Incentive
- Recruitment of patients completed for Part B of TACTI-002
- Immuteps partner, EOC Pharma, expands efti trial pipeline
- Chinese patent granted for anti-LAG-3 antibody LAG525
Later from Immutep
- Immutep granted Chinese Patent for eftilagimod alpha
- Immutep announces publication of SITC 2021 abstracts
- Immutep announces publication of SITC 2021 posters
- Immutep Global Webcast Slides to Discuss Clinical Results
- Phase II TACTI-002 trial recruitment successfully completed
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep